Avutometinib and Defactinib in Recurrent LGSOC: Results Explore the phase II trial results of avutometinib and defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

New Paper Alert: Avutometinib and Defactinib Combination for Recurrent LGSOC – Phase II Trial Results

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #LGSOC #Avutometinib #Defactinib #OvarianCancer

FDA Grants Accelerated Approval to Avutometinib and Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer: RAMP 201 trial results - OncoDaily FDA grants accelerated approval to Avutometinib and Defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer, marking a new targeted therapy option.

FDA Grants Accelerated Approval to Avutometinib and Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer: RAMP 201 trial results
@fda.gov

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #FDA #Avutometinib #Defactinib #OvarianCancer